‘Significant decline' in RSV-related illness in babies after high uptake of jab
Respiratory syncytial virus (RSV)
is a highly contagious virus that causes coughs and colds.
The main cause of bronchitis and pneumonia in very young children, it often puts significant strain on paediatric hospitals during the winter season.
Last year, for the first time, the
Department of Health
introduced a new vaccination programme in which babies born between September 2024 and February 2025 were eligible for the jab.
READ MORE
Almost 22,500 infants were immunised last year with Nirsevimab, a monoclonal antibody, with an uptake rate of approximately 83 per cent overall.
[
More than 600 people hospitalised with Covid, flu and RSV, says HSE
Opens in new window
]
This resulted in an estimated 65 per cent reduction in the number of RSV cases throughout the season when compared to the previous year, the department said.
Nirsevimab starts working as soon as the baby receives the injection and protects against RSV for 150 days, covering the very early period in a baby's life when most vulnerable to serious RSV-related illness.
Minister for Health
Jennifer Carroll MacNeill
described the data as 'compelling'.
'Last winter alone, there was an estimated 57 per cent reduction in emergency department presentations, a 76 per cent reduction in hospitalisations and a 65 per cent reduction in ICU admissions compared to the previous year,' she said.
'This significant decline highlights just how effective the immunisation has been in protecting our youngest and most vulnerable.'
Ms Carroll MacNeill announced an expansion of the scheme this year, with all babies under six months of age from September 1st being eligible for free immunisation at their local clinic.
[
Extending RSV immunisation would come with 'substantial' challenges
Opens in new window
]
'This is a vital step, as the risk of severe RSV infection is highest in the earliest months of life,' she said.
'I encourage all parents to take up this opportunity to safeguard their child's health. High uptake not only protects individual families, it also eases pressure on our health service, allowing resources to be directed where they're needed most.'
Deputy Chief Medical Officer Prof Ellen Crushell said prevention is 'always preferable to treatment'.
'Being able to prevent many babies from serious illness due to RSV is a wonderful step forward in child and population health,' she said.
'Paediatricians have described Nirsevimab as a 'gamechanger', reducing the number of illnesses and the severity of cases and reducing the spread of RSV to people who are vulnerable.'
The scheme will be operated by the
Health Service Executive (HSE)
. The Department of Health said further details on how to book appointments at local clinics will be available in the coming days.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Irish Times
an hour ago
- Irish Times
Smokers in Ireland will lose almost 5m years of life and cost health system €20bn
Current smokers in Ireland will collectively lose almost five million years of life and 2.5 million years of productivity, leading to healthcare costs of around €20.2 billion, according to research by the RCSI. The study, conducted at the RCSI School of Population Health, also estimates that current smokers in Ireland will spend a combined 5.9 million years living with smoking-related chronic diseases such as COPD, lung cancer, stroke and heart disease. The data used for the analysis was based on Irish population-level statistics for 2022, following smokers aged 15 to 85. At an individual level, those most affected were 20-year-old males who smoke daily. This group is expected to 'lose eight years of life, lose more than eight years of productivity and incur an additional €28,000 in healthcare costs over their lifetime compared to a non-smoker". READ MORE Dr Gintare Valentelyte, lead author, said the study is the first to 'provide evidence on the long-term outcomes and healthcare costs for the full smoking population in Ireland'. The researchers describe their study as 'timely' as it was completed ahead of a review of the current national tobacco control policy. Tobacco Free Ireland was launched in October 2013 and aimed to reduce the nationwide smoking prevalence rate to less than five per cent by 2025. 'It is clear that this target will not be met,' the study notes. Prof Frank Doyle, co-author of the research, said: 'There is an urgent need to reinvigorate the national tobacco policy discourse and re-focus policymakers on achieving this goal, as this research shows the costs of inaction both in lives lost and the billions of euros it will cost our health system and economy.' In 2023, smoking prevalence in Ireland stalled at 18 per cent, with other EU countries varying from eight per cent in Sweden to 37 per cent in Bulgaria, the study notes. Dr Paul Kavanagh, public health adviser to the HSE Tobacco Free Ireland Programme, said, despite some progress, 'smoking remains the greatest challenge facing population health in Ireland'. He said there is 'a need to strengthen proven measures like increasing tobacco taxation, accessible stop-smoking support and a new Tobacco Free Ireland plan to end the health, economic and wider social harms of smoking'. This research was funded by the HSE Tobacco Free Ireland Programme, as part of a collaboration with RCSI's School of Population Health. The study was also supported in part by a grant from Research Ireland.
RTÉ News
3 hours ago
- RTÉ News
Babies up to six months offered RSV immunisation for winter
Minister for Health Jennifer Carroll MacNeill has announced that an RSV immunisation programme will run throughout the forthcoming winter months and will be available to newborns and babies aged up to six months old. The immunisation will be offered in maternity hospitals to all babies born between 1 September this year and 28 February next year. It will also be available to babies aged less than six months old on 1 September, to offer them protection ahead of the expected seasonal upsurge in infection with RSV in the coming months. RSV (respiratory syncytial virus) is a common virus that causes coughs and colds. The HSE says almost all children get the virus by the time they are two years old, adding that it is the main cause of bronchiolitis and pneumonia in very young children. Most symptoms are mild, such as a runny nose, coughing and sneezing and recovery usually lasts two to three weeks without treatment or the need to see a GP. However, four in every 100 newborn babies are hospitalised due to RSV each winter, with some needing special treatment in intensive care units. Almost 22,500 infants were immunised against RSV last year with an uptake rate of approximately 83% overall. There was an estimated 65% reduction in the number of RSV cases throughout the winter season when compared with 2023-2024, the Department of Health said. Minister Carroll MacNeill said there was an estimated 57% reduction in emergency department presentations, 76% reduction in hospitalisations and a 65% reduction in ICU admissions for RSV-related illnesses last year. "For new parents, knowing their baby is protected against a potentially serious illness has brought immense reassurance," she said. She encouraged all parents to "take up this opportunity to safeguard their child's health". The RSV immunisation programme uses the monoclonal antibody nirsevimab, which the HSE says is not the same as a vaccine. While vaccines stimulate the immune system to produce antibodies, nirsevimab gives the antibodies directly to the immunised individual. "Nirsevimab works straight away so your baby is protected as soon as they get immunised," the HSE says. Nirsevimab is safe and it is more than 80% effective at protecting babies from hospitalisation due to complications of RSV infection, the HSE says. It protects newborns against RSV for 150 days and protects them when their risk of severe infection is high.
The Journal
3 hours ago
- The Journal
Children up to six months to be offered RSV vaccine in effort to reduce infections this winter
CHILDREN UP TO six months old will be provided with an Respiratory Syncytial Virus (RSV) vaccine as part of an expanded immunisation programme this winter. The immunisation will be offered in maternity hospitals to all babies born between 1 September 2025 and 28 February 2026. It will also be available to babies who are aged less than six months old on 1 September, to offer them protection ahead of the seasonal upsurge in infection with RSV. RSV is a common virus that causes coughs and colds. The HSE only gave the jab to newborns in maternity hospitals until now. Last year, almost 22,500 infants were immunised with Nirsevimab, a monoclonal antibody, with an uptake rate of around 83% overall. Advertisement As a result, the HSE says last winter there was an estimated 57% reduction in Emergency Department presentations, a 76% reduction in hospitalisations and a 65% reduction in ICU admissions compared to the previous year. Health Minister Jennifer Carroll MacNeill said this significant decline highlights just how effective the immunisation has been in protecting people. 'For new parents, knowing their baby is protected against a potentially serious illness has brought immense reassurance. 'I want to sincerely thank the dedicated teams across the Health Service Executive who made this success possible,' the minister said. 'I encourage all parents to take up this opportunity to safeguard their child's health. High uptake not only protects individual families it also eases pressure on our health service, allowing resources to be directed where they're needed most.' Deputy Chief Medical Officer Professor Ellen Crushell said Paediatricians have described Nirsevimab as a 'gamechanger'. Immunisations will be administered from 1 September in maternity hospitals and in clinics nationwide. The Department of Health said further details of immunisation clinics and how to book appointments will be announced in the coming days. Readers like you are keeping these stories free for everyone... A mix of advertising and supporting contributions helps keep paywalls away from valuable information like this article. Over 5,000 readers like you have already stepped up and support us with a monthly payment or a once-off donation. Learn More Support The Journal
